Observations with alpelisib in older patients ( ≥ 65 year of age) with breast cancer in a non-clinical trial setting

ConclusionOlder patients might derive further benefit from alpelisib if the adverse event profile of this agent, particularly the hyperglycemia, were able to be better managed.

http://link.springer.com/10.1007/s10549-021-06277-6

Source: Breast Cancer Research and Treatment - June 12, 2021 Category: Cancer & Oncology Source Type: research